Industry News

Europe Approves LumiCleanse Topical for Acne

KLOX Technologies has received CE mark approval in Europe for its topical photo-converter gel for the treatment of acne vulgaris. The gel is part of the company’s LumiCleanse System, a non-invasive acne vulgaris treatment that combines LED light and a topical photo-converter gel. According to a company press release, the non-abrasive and non-thermal treatment protocol—including skin preparation—can be performed in 15 minutes. Patients undergo treatment twice a week for six weeks. The system was approved for the treatment of all severities of acne vulgaris in Canada in September of this year.

Apollo Endosurgery Acquires Allergan Obesity Intervention Division

Apollo Endosurgery, a developer of medical devices and endoscopic surgical procedures, has entered into a definitive agreement to purchase the obesity intervention division of Allergan for up to $110 million. The total includes an upfront cash payment of $75 million, minority equity interest of $15 million, and up to $20 million in additional contingent consideration to be paid upon achievement of certain regulatory and sales milestones.

ALPHAEON Acquires Licensing Rights To TouchMD

ALPHAEON Corporation, a lifestyle healthcare company and wholly-owned subsidiary of Strathspey Crown Holdings LLC, has acquired worldwide licensing rights to TouchMD (www.touchmd.com), an interactive software platform that helps specialty physicians educate patients before, during and after practice consultation. The software was designed to increase practice conversion rates and enhance the patient experience.

Actavis Acquires Warner Chilcott

Actavis has completed its acquisition of Warner Chilcott in a stock-for-stock transaction valued at approximately $8.5 billion. The combination creates a global specialty pharmaceutical company with approximately $11 billion in anticipated pro forma combined annual 2013 revenue, and the third-largest specialty pharmaceutical business in the U.S. with approximately $3 billion in annual revenue focused on the core therapeutic categories of women's health, urology, gastroenterology and dermatology.